医疗事务的评价(美国)- 慢性骨髓性白血病
市场调查报告书
商品编码
1803884

医疗事务的评价(美国)- 慢性骨髓性白血病

Medical Affairs Reputations (US) - Chronic Myeloid Leukemia

出版日期: | 出版商: FirstWord Group | 英文 | 商品交期: 最快1-2个工作天内

价格
简介目录

本报告是根据血液科医师和肿瘤科医师的定量调查,检视了美国支持慢性骨髓性白血病 (CML) 治疗的医疗事务团队的绩效和声誉。报告提供了医生互动频率、首选沟通管道、对当前支援的满意度以及关键未满足需求的数据。竞争洞察包括竞争基准、团队的优势和不足之处,以及医生改进医疗事务服务、满足临床和资讯需求的优先事项。

关键问题

  • 1.医师与医疗事务团队的互动频率为何?这个频率是增加了还是减少了?
  • 2.医师目前如何使用医疗事务服务?
  • 3.医疗事务支援的哪些对医师最重要?他们对所提供的支援有多满意?
  • 4.医师希望与医学事务团队进行哪种类型的互动?互动频率如何?
  • 5.医学事务团队在多大程度上满足了医师的需求?
  • 6.医学事务团队的表现是否低于或超过了其针对特定品牌的目标?
  • 7.未来如何改善医学事务服务,以便更好地满足医师的需求?
  • 8.竞争对手的医学事务团队在哪些方面最薄弱,哪些方面最强?

领导品牌

  • 博舒替尼 (Boslif)
  • 伊曲康唑 (Iclusig)
  • 舒必利 (Sucembrix)
  • 施必利 (Sprycel)(达沙替尼)
  • 泰斯纳 (Tasigna)(尼洛替尼)
  • 奥力伐替尼(HQP1351)

调查手法:

FirstView 报告是基于对 LiMATM 医生进行的定量调查而开发。 LiMATM 是全球最大的医生名录,涵盖超过 300 万名医生。每位医生均根据严格的筛选标准精心挑选,以确保收集到的见解具有相关性和可靠性,能够反映顶尖医疗专业人士的真实意见和经验。调查结果以易于理解的图表形式呈现,方便您快速掌握和分析数据。凭藉 LiMATM 广泛的覆盖范围和精准度,FirstView 报告提供无与伦比的数据驱动洞察,指导策略规划,并帮助您在快速发展的医疗保健领域保持领先地位。

我们报告的独特之处:

FirstWord Reports 是值得信赖的行业领导者,专注于製药业,为生物製药专业人士和决策者提供深入、可操作的洞察。我们深厚的行业知识使我们能够提供相关且有价值的洞察,帮助客户掌握新兴趋势,有​​效应对复杂挑战。凭藉广泛的研究以及来自领先专家和关键意见领袖 (KOL) 的独立客观见解,我们的报告能够提供您所需的准确性和可靠性。独家访谈和数据,以及持续的市场监测,确保全面了解市场动态。我们的报告涵盖 40 多个活跃的疾病领域,提供包括关键意见领袖 (KOL) 洞察和定量医生调查在内的医生情报,以及行业专家对医疗事务、数位健康、销售和行销、市场准入和其他领域问题的看法,使您能够做出更明智的数据驱动决策,并在快速变化的行业中保持竞争力。

简介目录

This report examines the performance and reputation of Medical Affairs teams supporting therapies for chronic myeloid leukemia (CML) in the US, based on a quantitative survey of haemato-oncologists. It provides data on physician interaction frequency, preferred engagement channels, satisfaction with current support, and key unmet needs. Insights include competitive benchmarking across brands, areas where teams are exceeding or falling short, and physician priorities for improving Medical Affairs services to better meet clinical and informational needs.

Key Questions Answered:

  • 1. How frequently do physicians interact with Medical Affairs teams, and is the frequency of this interaction increasing or decreasing?
  • 2. In what ways do physicians currently use the services provided by Medical Affairs teams?
  • 3. What aspects of Medical Affairs support are most important to physicians and how satisfied are they with the support provided?
  • 4. What are the preferred mediums for interactions between physicians and Medical Affairs teams and what is the preferred frequency of these interactions?
  • 5. How successful are Medical Affairs teams at meeting physician needs?
  • 6. Are Medical Affairs teams falling short or exceeding goals with any particular brands?
  • 7. How can Medical Affairs services be improved to better meet the needs of physicians in the future?
  • 8. In what areas are your competitors' Medical Affairs teams weakest and strongest?

Key Brands:

  • Bosulif (bosutinib)
  • Iclusig (ponatinib)
  • Scemblix (asciminib)
  • Sprycel (dasatinib)
  • Tasigna (nilotinib)
  • olverembatinib (HQP1351)

Methodology:

FirstView reports are developed from quantitative surveys conducted with physicians selected through LiMATM, the world's largest physician directory, containing over 3 million vetted and verified physicians. Each physician is carefully chosen based on strict screening criteria to ensure the insights gathered are both relevant and reliable, reflecting the true sentiments and experiences of leading medical professionals. The findings are presented in a series of easy-to-interpret charts, enabling you to quickly grasp and analyze the data. By leveraging the vast reach and precision of LiMATM, FirstView Reports provide unparalleled, data-driven insights to guide your strategic planning and help you stay ahead in a fast-evolving healthcare landscape.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.